STAT+: FDA officials push for long-term monitoring of autoimmune patients receiving CAR-T therapy
Stat News • 2/2/2026 – 2/3/2026
Summary
FDA officials are advising drug developers to study the long-term effects of CAR-T therapy in autoimmune conditions. This recommendation is based on concerns that the therapies could carry risks.
Advertisement
Lindy Score Breakdown (V4.2)
60d
Age
1
Sources
from cluster
1423
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1423/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1423/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 59 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • Today
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
Supreme Court rules against conversion therapy ban
Stat News • 2 days ago
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
Stat News • Today
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • Today
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 1 day ago
Supreme Court conversion therapy decision could ripple through medicine
Stat News • Today
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 1 day ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago